Search International and National Patent Collections

1. (WO2018086446) SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY

Pub. No.:    WO/2018/086446    International Application No.:    PCT/CN2017/106616
Publication Date: Fri May 18 01:59:59 CEST 2018 International Filing Date: Wed Oct 18 01:59:59 CEST 2017
IPC: C07D 405/14
C07D 401/12
A61K 31/517
A61P 35/00
A61P 25/28
Applicants: WEISHANG (SHANGHAI) BIO-PHARMACEUTICAL CO., LTD.
威尚(上海)生物医药有限公司
Inventors: ZHONG, Wei
钟卫
Title: SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY
Abstract:
Disclosed is a substituted quinazoline compound having blood-brain barrier penetration capability. The structural formula of the compound is as represented by formula (I). The substituted quinazoline compound of the present invention, and a derivative and a pharmaceutical salt thereof have unexpected blood-brain barrier penetration capability, and pharmaceutical characteristics which enable them to serve as protein kinase inhibitors. They are particularly used for medical situations mediated by some activated and mutated forms of an epidermal growth factor receptor, and can be used for treating or preventing disorders associated with abnormal protein kinase activity, such as cancer, brain metastasis, meningeal metastasis, and central nervous diseases.